Articles and application notes
6 Misconceptions about automating cell therapy manufacturing
By using automation to minimize human interaction and time and resource requirements, you can increase your product’s speed to market and mitigate many of the risks and costs associated with commercialization.
AAV production using microcarriers
Large-scale AAV production processes are needed to industrialize gene therapies. This customer case study describes microcarrier culture in a 1 L bioreactor.
CAR T cell process development study
Manual, open processing is not ideal for commercial production of chimeric antigen receptor (CAR T) cells. This study describes development of a closed and semi-automated process that can be adapted for GMP compliance and CAR T developers’ needs.
Case study: lentiviral vector process development
Development of a scalable process to produce high-yield lentiviral vector batches using stable, suspension-based production methods.
Consistent cord blood cryopreservation
Customer study shows reproducible cord blood freezing without liquid nitrogen.
Controlled endpoint in cryopreservation
This study was designed to answer the question: When is it safe to transfer cell samples from a controlled-rate freezer to liquid nitrogen storage?
Developments in cell expansion for cell processing
Expand your knowledge on perfusion, our rocking technology and more by reading through our latest papers and posters.
Enabling LN2-free large-volume cryopreservation in vials
Cooling protocol and proof-of-concept study for the cryopreservation of large-volume biological samples in cryovials. Achieve high and consistent post-thaw recovery of up to 50 mL in this liquid nitrogen-free cell freezing method.
Going liquid nitrogen-free for low-impact cryopreservation
Switching to a liquid nitrogen-free controlled-rate freezer can reduce carbon emissions by 87% over 10 yr and decrease operating costs by up to 97%. Read our study to see how you could minimize the environmental impact of your cryopreservation.
How and when to get started with GMP
Two cell therapy experts provide practical advice on when and how to start thinking about compliance with good manufacturing practices (GMP).
Interrupted cooling in cryopreservation
How does a power interruption during cooling affect post-thaw cell viability? This study demonstrates minimal effect of power outages and interrupted cooling during cryopreservation when using a VIA Freeze controlled-rate freezer.
Is a rapid cooling step needed?
This study shows comparable results when freezing cells with or without a rapid-cooling nucleation step.
Lentiviral vector upstream process
Upstream lentiviral vector process with stable producer cell line that can be adapted for commercial manufacturing. Scales linearly from 5 to 28 L in Xcellerex bioreactors yielding ≥ 1010 TU/L of LV-GFP.
Natural killer cells manufacturing
Workflow for NK cell production from apheresis units. Isolation, xeno-free expansion, harvest, and cryopreservation amenable to GMP manufacturing.
Optimize your cell therapy process — a guide to cell thawing
Cell therapy thawing is a complex and critical step in getting treatments to patients in need. We developed this guide to outline the science of thawing and present methods for maintaining cell viability and treatment efficacy.
Primary clarification of lentiviral vectors
Study describes a protocol to separate lentiviral vectors from bioreactor-derived suspension cells and debris using a scalable filter train.
Reducing gene therapy production costs
In an industry forum, leaders discussed challenges and insights related to reducing the cost of goods for gene therapy.
The Supply Chain Challenge
Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Here two industry experts provide practical advice on strategies to meet supply chain challenges.
Tumor-infiltrating lymphocytes as cell therapies
TILs are showing promise as cancer treatments for solid tumors. Learn what they are and how they differ from CAR T cells.
Security of supply in cell and gene therapy manufacturing
Building an adequate supply chain with the necessary equipment and protocols is critical for companies pursuing cell and gene therapies. Cytiva realized the importance of this need and implemented a Security of supply program.